Kalaris Therapeutics, Inc. - Asset Resilience Ratio
Kalaris Therapeutics, Inc. (KLRS) has an Asset Resilience Ratio of 57.18% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Kalaris Therapeutics, Inc. to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Kalaris Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Kalaris Therapeutics, Inc..
Liquid Assets Composition Over Time
This chart breaks down Kalaris Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Kalaris Therapeutics, Inc.'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $62.79 Million | 57.18% |
| Total Liquid Assets | $62.79 Million | 57.18% |
Asset Resilience Insights
- Very High Liquidity: Kalaris Therapeutics, Inc. maintains exceptional liquid asset reserves at 57.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kalaris Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Kalaris Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Kalaris Therapeutics, Inc. (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Kalaris Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.37% | $19.93 Million | $121.74 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $118.55 Million | -- |
| 2021-12-31 | 16.21% | $46.46 Million | $286.59 Million | -46.80pp |
| 2020-12-31 | 63.01% | $233.66 Million | $370.82 Million | +16.40pp |
| 2019-12-31 | 46.62% | $64.99 Million | $139.42 Million | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more